Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionNasal inhaled combination product containing mometasone furoate and oxymetazoline
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationRhinitis
Indication DetailsTreat allergic rhinitis
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today